NCT05472662

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

A Single-dose, Randomised, Double-blind, Controlled, 2-way Cross-over Study to Assess the Potential for Bronchoconstriction of the New Propellant HFA-152a Versus the Marketed HFA-134a Propellant, in Adult Subjects With Mild Asthma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Chiesi Farmaceutici S.p.A. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way cross-over study to evaluate the potential for bronchoconstriction of the new HFA-152a propellant (single dose) versus the marketed HFA-134a propellant (single dose) in adults with mild asthma. HFA=Hydrofluoroalkane

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	Placebo 152a	Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
DRUG	Placebo 134a	Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant

Timeline

• Start date: 2022-08-03
• Primary completion: 2022-10-31
• Completion: 2022-10-31
• First posted: 2022-07-25
• Last updated: 2024-10-15
• Results posted: 2024-10-15

Locations

1 site across 1 country: United Kingdom